Rigel Pharmaceuticals, Incorporated

Rutgers, the State University of New Jersey

Ribogene, Inc.

Michael B Mathews

Michael G Katze

Julia C Watson

Gary Witherell

Vincent Miles

Hartmut M Hanauske-Abel

Tsafi Pe'ery

Vincent J Miles

Mainul Hoque

Mainul Hogue

Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.

Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A

Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.

Method of inhibiting nonsense-mediated mRNA decay

Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.

Method for selective inactivation of viral replication

Growing community of inventors

Montclair, NJ, United States of America

Michael B Mathews